NCT06553209

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis

A Randomized, Double-blind, Single/Multiple Dose Escalation, Placebo-controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM512 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: Keymed Biosciences Co.Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
BIOLOGICAL	CM512	CM512 injection
DRUG	Placebo	Placebo

Timeline

• Start date: 2024-09-02
• Primary completion: 2025-08-26
• Completion: 2025-09-12
• First posted: 2024-08-14
• Last updated: 2025-09-22

Locations

1 site across 1 country: China